Development of a PET radioligand selective for cerebral amyloid angiopathy.

ABSTRACT:

Introduction

Positron emission tomography (PET) using radiolabeled amyloid-binding compounds has advanced the field of Alzheimer's disease (AD) by enabling detection and longitudinal tracking of fibrillar amyloid-β (Aβ) deposits in living people. However, this technique cannot distinguish between Aβ deposits in brain parenchyma (amyloid plaques) from those in blood vessels (cerebral amyloid angiopathy, CAA). Development of a PET radioligand capable of selectively detecting CAA would help clarify its contribution to global brain amyloidosis and clinical symptoms in AD and would help to characterize side-effects of anti-Aβ immunotherapies in AD patients, such as CAA.

Methods

A candidate CAA-selective compound (1) from a panel of analogues of the amyloid-binding dye Congo red w

SUBMITTER: Abrahamson EE 

PROVIDER: S-EPMC8788879 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature